KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Deferred Revenue (2020 - 2025)

Recursion Pharmaceuticals' Current Deferred Revenue history spans 6 years, with the latest figure at $37.6 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 39.12% year-over-year to $37.6 million; the TTM value through Dec 2025 reached $37.6 million, down 39.12%, while the annual FY2025 figure was $37.6 million, 39.12% down from the prior year.
  • Current Deferred Revenue reached $37.6 million in Q4 2025 per RXRX's latest filing, down from $47.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $73.1 million in Q2 2023 to a low of $2.5 million in Q1 2022.
  • Average Current Deferred Revenue over 5 years is $37.1 million, with a median of $38.6 million recorded in 2025.
  • Peak YoY movement for Current Deferred Revenue: tumbled 75.0% in 2022, then surged 2210.44% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $10.0 million in 2021, then surged by 467.26% to $56.7 million in 2022, then plummeted by 35.79% to $36.4 million in 2023, then surged by 69.57% to $61.8 million in 2024, then crashed by 39.12% to $37.6 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Current Deferred Revenue are $37.6 million (Q4 2025), $47.4 million (Q3 2025), and $39.7 million (Q2 2025).